We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections.
- Authors
Hajime Yasuda; Yosuke Mori; Asako Chiba; Jie Bai; Goh Murayama; Yasushi Matsushita; Sachiko Miyake; Norio Komatsu
- Abstract
We previously reported elsewhere of a follicular lymphoma patient suffering from persistent COVID-19 pneumonia that was still ongoing at 2 months after onset. We provide a follow-up report of the case along with a literature review of immunocompromised lymphoma patients experiencing prolonged COVID-19 infections. Although requiring a full 1 year, the presented case eventually achieved spontaneous resolution of COVID-19 pneumonia. Anti-SARS-CoV-2 antibodies could not be detected throughout the disease course, but COVID-19-directed T-cell response was found to be intact. The patient also developed secondary immune thrombocytopenia subsequent to COVID-19 pneumonia. We found 19 case reports of immunocompromised lymphoma patients with prolonged COVID-19 infections in the literature. All 5 patients who died did not receive convalescent plasma therapy, whereas resolution of COVID-19 infection was achieved in 8 out of 9 patients who received convalescent plasma therapy. We demonstrate through the presented case that while time-consuming, resolution of COVID-19 infections may be achieved without aid from humoral immunity if cellular immunity is intact. Immunocompromised lymphoma patients are at risk of a prolonged disease course of COVID-19, and convalescent plasma therapy may be a promising approach in such patients. Persisting clinical infections and prolonged viral shedding of COVID-19 in immunocompromised patients is a rapidly emerging issue of concern. Persisting COVID-19 infections not only threaten the well-being of the patient, but may also be a potential long-term contagious threat to the environment, and special care must be provided concerning in-hospital isolation and self-quarantine periods. We report an immunocompromised lymphoma patient recovering from a 1-year disease course of COVID-19 pneumonia along with a review of the literature.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2021, Vol 21, Issue 10, pe810
- ISSN
2152-2650
- Publication type
Article
- DOI
10.1016/j.clml.2021.07.004